In this episode of The Pediatric Pharmacist Review, we delve into the 2025 KIDs List—the Pediatric Pharmacy Association's updated guide highlighting key potentially inappropriate medications in pediatric care. This comprehensive list serves as a critical resource for clinicians aiming to enhance medication safety and optimize pharmacotherapy in pediatric populations. Meet the Experts: Dr. Rachel S. Meyers brings a wealth of experience as a Clinical Professor at Rutgers University and a Pediatric Clinical Pharmacist at Cooperman Barnabas Medical Center. Her clinical insights and academic contributions have significantly influenced pediatric pharmacy practice. Dr. David Hoff serves as the Pharmacy Director for Acute Care at Children’s Minnesota and holds the position of Section Editor at JPPT. With over 30 years of experience, he has been instrumental in developing and updating the KIDs List, ensuring it reflects the latest evidence and best practices. Key Discussion Points: The evolution and significance of the KIDs List in pediatric pharmacotherapy Strategies for integrating the KIDs List into clinical practice The impact of inappropriate medications on pediatric patient outcomes Collaborative efforts in pediatric medication safety Further Reading: For a comprehensive understanding, access the full 2025 KIDs List here: 2025 KIDs List PDF
